Most Read Articles
3 years ago

WHO (2012) estimates that around 450 million people suffer from mental illness, with one–in–four families having at least one member with a mental illness at any point in time. According to the Malaysian Mental Health Association, mental illness is often misunderstood. For centuries, it has been seen as either possession by evil spirits, a moral weakness or punishment from a higher being. Those suffering from mental illness are commonly perceived to be restless, violent and unpredictable.

10 months ago
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
Radha Chitale, one year ago

Over 15 percent of lymphoma survivors who receive autologous hematopoietic stem-cell transplantation (auto-HCT) as adults suffer left ventricular systolic dysfunction (LVSD) and potential heart failure, new research shows.


one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

TNF-alpha medication ups risk of tuberculosis

24 days ago

Patients treated with tumour necrosis factor (TNF)-α antagonists may be at a greater risk of tuberculosis (TB), although the biological mechanism underlying this association needs to be elucidated, according to a meta-analysis.

Researchers searched databases including Medline, Embase and Cochrane library for randomised controlled trials (RCTs) reporting TB risk among patients treated with any of the currently available TNF-α antagonists: etanercept (ETN), adalimumab (ADA), infliximab (IFX), golimumab (GOL) and certolizumab pegol (CZP). Exclusion criteria included studies based on unoriginal data, those without data on TB incidence, those that did not observe TB events and articles not published in English.

A total of 29 RCTs involving 11,879 patients were included (n=14 for IFX; n=9 for ADA; n=2 for GOL; n=1 for ETN; n=3 for CZP). A random-effect model was used to calculate odds ratios (ORs) with 95 percent CIs, and subgroup analyses were performed based on type of medication, disease under treatment and TB endemicity. Quality of evidence was evaluated using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach.

Pooled data revealed that TB developed in 45 of 7,912 patients in the TNF-α arms and in three of 3,967 patients in the control arms, yielding an OR of 1.94 (1.10 to 3.44; p=0.02). Results from the subgroup analyses indicated that the effect of TNF-α treatment on TB risk was greater among patients treated for rheumatoid arthritis (OR, 2.29; 1.09 to 4.78; p=0.03). The quality of evidence was low as per the GRADE system.

The present data highlight the importance of considering the potential increase in the risk of TB in the clinical decision concerning treatment with anti-TNF-α drugs; patients should be screened for LTBI and anti-TB prophylaxis before making any decision.

TNF-α antagonists are widely used in in the treatment of rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis and other immune-mediated or inflammation-related diseases. These agents potentially impact on the protective mechanism against infections, especially TB, by increasing the phagocytic capacity of macrophages and enhancing intracellular killing of mycobacterium via the generation of reactive nitrogen and oxygen intermediates. [J Pathol 2008;214:149–60; Ann Rheum Dis 2015;74:1212–17]

“TNF-α is also involved in the pathological changes of latent tuberculous infection, especially in maintaining the formation and function of granuloma which prevents mycobacterium from disseminating into the blood. These TNF-mediated immune mechanisms may explain the reason for the increased risk of TB in patients receiving anti-TNF agents’ treatment,” researchers said.

“Further high-quality research regarding the long-term safety of biologics is needed to improve the safety of biological treatment in clinical use,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
3 years ago

WHO (2012) estimates that around 450 million people suffer from mental illness, with one–in–four families having at least one member with a mental illness at any point in time. According to the Malaysian Mental Health Association, mental illness is often misunderstood. For centuries, it has been seen as either possession by evil spirits, a moral weakness or punishment from a higher being. Those suffering from mental illness are commonly perceived to be restless, violent and unpredictable.

10 months ago
Orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide were effective in achieving weight loss among overweight and obese adults at 52 weeks, a recent study found. Phentermine-topiramate and liraglutide were associated with the highest odds of achieving at least 5 percent weight loss.
Radha Chitale, one year ago

Over 15 percent of lymphoma survivors who receive autologous hematopoietic stem-cell transplantation (auto-HCT) as adults suffer left ventricular systolic dysfunction (LVSD) and potential heart failure, new research shows.


one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.